FEEDS
EANS-Adhoc: Oxygen Biotherapeutics Reports Second Quarter FY2012 Financial Results. -Management to host teleconference to discuss financial results on December 19-
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. quarterly report 17.12.2011 MORRISVILLE, NC, December 16, 2011 — Oxygen ... weiter zur Pressemitteilung von Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics Announces Registered Financing for up to $7.5 million in Gross Proceeds
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. 09.12.2011 MORRISVILLE, NC, December 9, 2011 - Oxygen Biotherapeutics, Inc. ... weiter zur Pressemitteilung von Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics macht Sekundärkotierung an SIX rückgängig
Ad-hoc-Mitteilung übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. 28.10.2011 MORRISVILLE, North Carolina, USA — Oxygen Biotherapeutics, Inc. (NASDAQ & SIX Swiss ... weiter zur Pressemitteilung von Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics to Voluntarily Withdraw Secondary Listing from SIX Swiss Stock Exchange
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. 28.10.2011 MORRISVILLE, NC, October 27, 2011 - Oxygen Biotherapeutics, Inc. ... weiter zur Pressemitteilung von Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics Names Dr. Ronald Blanck Chairman of the Board
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. 01.10.2011 MORRISVILLE, NC, September 30, 2011— Oxygen Biotherapeutics, Inc. ... weiter zur Pressemitteilung von Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics Reports First Quarter FY2012 Financial Results and Announces Conference Call and Webcast for Shareholders
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. quarterly report 20.09.2011 MORRISVILLE, NC, September 19, 2011 — Oxygen ... weiter zur Pressemitteilung von Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics Announces Dismissal of Chris J. Stern as CEO and Appointments of Michael B. Jebsen as Interim CEO and Rene Eckert as Interim Chairman. -Oxygen Biotherapeutics to reschedule its 2011 General Annual Meeting of Stockholder
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. 25.08.2011 MORRISVILLE, NC, August 24, 2011— The Board of Directors of ... weiter zur Pressemitteilung von Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics and Aurum Biosciences Sign Letter of Intent to Explore the Use of Oxycyte® PFC for Imaging and Therapeutic Intervention of Acute Ischemic Stroke
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Research & Development 25.07.2011 MORRISVILLE, NC, July 25, 2011 - Oxygen ... weiter zur Pressemitteilung von Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics und Aurum Biosciences unterzeichnen Absichtserklärung zur Erforschung von Oxycyte® PFC für Imaging und therapeutische Interventionen bei akutem ischämischem Hirnschlag.
Ad-hoc-Mitteilung übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. Forschung/Entwicklung 25.07.2011 MORRISVILLE, North Carolina, USA — Oxygen Biotherapeutics, Inc. ... weiter zur Pressemitteilung von Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics Reports Financial Results for Fiscal Year 2011
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. 15.07.2011 MORRISVILLE, NC, July 14, 2011 — Oxygen Biotherapeutics, Inc. (NASDAQ ... weiter zur Pressemitteilung von Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics Inc. / Ausdehnung der Phase IIb für STOP TBI nach Indien bewilligt.
Ad-hoc-Mitteilung übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. Forschung/Entwicklung 07.06.2011 MORRISVILLE, North Carolina, USA — Oxygen Biotherapeutics, Inc. ... weiter zur Pressemitteilung von Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics Receives Approval to Expand Phase IIb Trials with Oxycyte® PFC for Traumatic Brain Injury into India
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Research & Development 07.06.2011 MORRISVILLE, NC, June 7, 2011 - Oxygen ... weiter zur Pressemitteilung von Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics Reports Financial Results For Third Quarter FY2011
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. 9-month report/Biotechnology 22.03.2011 MORRISVILLE, NC, March 21, 2011 — Oxygen ... weiter zur Pressemitteilung von Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics and Hackensack University Medical Center Sign Research Contract Funded by the U.S. Department of Defense to Study Wound Healing Properties of Wundecyte™ Gel
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Contracts 28.01.2011 DURHAM, NC, January 28, 2011 - Oxygen Biotherapeutics, Inc. ... weiter zur Pressemitteilung von Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics Inc. / US-Verteidigungsministerium finanziert Wundecyte-Studie
Ad-hoc-Mitteilung übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. Verträge 28.01.2011 DURHAM, North Carolina - Oxygen Biotherapeutics, Inc. (NASDAQ & SIX Swiss Exchange: ... weiter zur Pressemitteilung von Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics unterzeichnet Vertriebsabkommen für Dermacyte-Produkte mit Schweizer Gesellschaft
Ad-hoc-Mitteilung übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. Verträge 13.01.2011 DURHAM, North Carolina - Oxygen Biotherapeutics, Inc. (NASDAQ & SIX Swiss Exchange: ... weiter zur Pressemitteilung von Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics Signs Agreement to Sell DERMACYTE Products to Swiss Sales and Distribution Company
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Contracts 13.01.2011 DURHAM, NC, January 13, 2011 - Oxygen Biotherapeutics, Inc. ... weiter zur Pressemitteilung von Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics Reports Second Quarter FY2011 Financial Results
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. quarterly report 10.12.2010 DURHAM, NC, December 9, 2010 — Oxygen Biotherapeutics, ... weiter zur Pressemitteilung von Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics vereinbart mit dem Vatea Fund eine Darlehensfinanzierung über 5 Millionen UD-Dollar
Ad-hoc-Mitteilung übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. Biotechnologie 13.10.2010 DURHAM, North Carolina - Oxygen Biotherapeutics, Inc. (NASDAQ & SIX Swiss ... weiter zur Pressemitteilung von Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics Enters into Purchase Agreement to Sell $5 million of Unsecured Promissory Notes to Vatea Fund
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Biotechnology 13.10.2010 DURHAM, NC, September 13, 2010 - Oxygen Biotherapeutics, ... weiter zur Pressemitteilung von Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics erhält DSMB Bewilligung für die nächste Kohorte der klinischen Versuche der Phase II-b Studie STOP-TBI
Ad-hoc-Mitteilung übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. Forschung/Entwicklung/Biotechnologie 23.09.2010 DURHAM, North Carolina, USA — Oxygen Biotherapeutics, ... weiter zur Pressemitteilung von Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics Receives DSMB Approval to Proceed to the Next Cohort in Its Phase II-B Clinical Trial for Traumatic Brain Injury
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Research & Development/Biotechnology 23.09.2010 DURHAM, NC, September 23, 2010 - ... weiter zur Pressemitteilung von Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics und U.S. Navy vertiefen Zusammenarbeit
Ad-hoc-Mitteilung übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. Forschung/Entwicklung/Biotechnologie 20.09.2010 DURHAM, North Carolina, USA — Oxygen Biotherapeutics, ... weiter zur Pressemitteilung von Oxygen Biotherapeutics Inc.
EANS-Adhoc: U.S. Navy Broadens CRADA with Oxygen Biotherapeutics
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. Research & Development 20.09.2010 DURHAM, NC, September 20, 2010 - Oxygen ... weiter zur Pressemitteilung von Oxygen Biotherapeutics Inc.
EANS-Adhoc: Oxygen Biotherapeutics Reports First Quarter FY2011 Financial Results
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. quarterly report/Biotechnology 10.09.2010 DURHAM, NC, September 9, 2010 — Oxygen ... weiter zur Pressemitteilung von Oxygen Biotherapeutics Inc.
